MicroRNA-708 inhibits the proliferation and chemoresistance of pancreatic cancer cells

Liu, Wensong; Lu, Yunjie; Zhang, Dong; Shi, Longqing; Zu, Guangchen; Hua, Yan; Sun, Donglin

doi:10.32604/biocell.2020.08613

Cited by 9 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same study also identified the downregulation of miR-708 in these cells compared to healthy controls ( 8 ). In this regard, several studies have discovered that miR-485 and miR-708 directly target the 3′-UTR of survivin mRNA and downregulate its production ( 74 , 75 ); hence, miR-485 and miR-708 downregulation in CD4 + T cells contributes to survivin overexpression and thus defective apoptosis regulation. Similarly, miR-34a expression was lower in PBMCs from MS patients than healthy controls, and it is negatively associated with survivin mRNA expression and serum level ( 73 ).…”

Section: Irregular Expression Of Survivin-specific Micrornas In Speci...mentioning

confidence: 99%

RETRACTED: Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies

et al. 2022

View full text Add to dashboard Cite

It has been well established that the etiopathogenesis of diverse autoimmune diseases is rooted in the autoreactive immune cells’ excessively proliferative state and impaired apoptotic machinery. Survivin is an anti-apoptotic and mitotic factor that has sparked a considerable research interest in this field. Survivin overexpression has been shown to contribute significantly to the development of autoimmune diseases via autoreactive immune cell overproliferation and apoptotic dysregulation. Several microRNAs (miRNAs/miRs) have been discovered to be involved in survivin regulation, rendering the survivin-miRNA axis a perspective target for autoimmune disease therapy. In this review, we discuss the role of survivin as an immune regulator and a highly implicated protein in the pathogenesis of autoimmune diseases, the significance of survivin-targeting miRNAs in autoimmunity, and the feasibility of targeting the survivin-miRNA axis as a promising therapeutic option for autoimmune diseases.

show abstract

Section: Irregular Expression Of Survivin-specific Micrornas In Speci...mentioning

confidence: 99%

RETRACTED: Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies

et al. 2022

View full text Add to dashboard Cite

show abstract

“…It is necessary to estimate the long-term survival of patients with PDAC for individualized therapy. Recent studies developed various tumor molecular classifications to predict the survival outcomes of PDAC patients based on gene expression and mutation profiling, whereas LncRNAs were largely neglected [ 43 , 44 , 45 ]. In this study, we constructed a risk-score prognostic model according to immune-related genes and LncRNAs.…”

Section: Discussionmentioning

confidence: 99%

Single Cell RNA-Seq Identifies Immune-Related Prognostic Model and Key Signature-SPP1 in Pancreatic Ductal Adenocarcinoma

Chen

Wang

Liu

et al. 2022

Genes

View full text Add to dashboard Cite

There are no reliable biomarkers for early diagnosis or prognosis evaluation in pancreatic ductal adenocarcinoma (PDAC). Multiple scRNA-seq datasets for PDAC were retrieved from online databases and combined with scRNA-seq results from our previous study. The malignant ductal cells were identified through calculating copy number variation (CNV) scores. The robust markers of malignant ductal cells in PDAC were found. Five immune-related signatures, including SPP1, LINC00683, SNHG10, LINC00237, and CASC19, were used to develop a risk score formula to predict the overall survival of PDAC patients. We also constructed an easy-to-use nomogram, combining risk score, N stage, and margin status. The expression level of SPP1 was related to the prognosis and immune regulators. We found that SPP1 was mainly expressed in ductal cells and macrophages in PDAC. In conclusion, we constructed a promising prognostic model based on immune-related signatures for PDAC using scRNA-seq and TCGA_PAAD datasets.

show abstract

“…It is necessary to estimate the long-term survival of patients with PDAC for individualized therapy. Recent studies developed various tumor molecular classi cations to predict survival outcomes of PDAC patients based on genes expression, mutation pro ling, whereas LncRNAs were largely neglected [35][36][37]. In this study, we constructed risk score prognostic model according to immune related genes and LncRNAs.…”

Section: Discussionmentioning

confidence: 99%

Construction of immune related prognostic model for pancreatic ductal adenocarcinoma based on single cell RNA-seq analysis

Chen

Wang

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

There are no reliable biomarkers for early diagnosis and prognosis evaluation in pancreatic ductal adenocarcinoma (PDAC). Single cell RNA-seq (scRNA-seq) revealed tumor microenvironment heterogeneity in PDAC. This study aimed to construct immune-related prognostic model of PDAC based on scRNA-seq. Multiple scRNA-seq datasets for PDAC were retrieved from online databases and combined with scRNA-seq results from and our previous study. The malignant ductal cells were identified through calculating CNV scores. The common immune related signatures were identified to develop prognostic model using scRNA-seq and TCGA_PAAD datasets. The expression and distribution of key signature gene SPP1 was explored by scRNA-seq and multicolor immunohistochemistry. The robust markers of malignant ductal cells in PDAC were found. Five immune-related signatures, including SPP1, LINC00683, SNHG10, LINC00237, CASC19 were used to develop risk score formula to predict the overall survival of PDAC patients. We also constructed an easy-to-use nomogram, combining risk score, N stage, and margin status of PDAC. The expression level of SPP1 was related to the prognosis and immune regulators. In addition, we found that SPP1 was mainly expressed in ductal cells and macrophages in PDAC. In conclusion, we constructed a promising prognostic model based on immune related genes and LncRNAs for PDAC using scRNA-seq and TCGA_PAAD datasets.

show abstract

MicroRNA-708 inhibits the proliferation and chemoresistance of pancreatic cancer cells

Cited by 9 publications

References 0 publications

RETRACTED: Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies

RETRACTED: Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies

Single Cell RNA-Seq Identifies Immune-Related Prognostic Model and Key Signature-SPP1 in Pancreatic Ductal Adenocarcinoma

Construction of immune related prognostic model for pancreatic ductal adenocarcinoma based on single cell RNA-seq analysis

Contact Info

Product

Resources

About